PATENT
Docket No. 204372000320

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office on November 4, 1996

Nancy J. Robins

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Lynn E. Spitler et al.

Serial No.: 08/288,057

Filing Date: 10 August 1994

For: PROSTATIC CANCER VACCINE

Examiner: P. Gambel

Group Art Unit: 1816

DECLARATION OF MICHAEL MASTRANGELO, MD PURSUANT TO 37 C.F.R § 1.132

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

I, Michael Mastrangelo, MD, declare as follows:

1. I am a Professor of Medicine, and Associate Clinical Director of the Jefferson Cancer Center in Philadelphia, Pennsylvania. A copy of my *Curriculum Vitae* is attached hereto as Exhibit A. I am Chairman of the Scientific Advisory Board of Jenner Technologies, the assignee in this application, and a shareholder in the company.

2. I have reviewed the Declaration Under 37 C.F.R. 1.132 prepared by Dr. Lynn E. Spitler describing the results of a clinical study directed to the use of prostate specific antigen (PSA) as an active ingredient in an antiprostate cancer vaccine. I am also familiar with the study itself, and with the results that were obtained.

3. The purpose of the study was to obtain evidence that the vaccines would raise a sufficient cellular immune response to have a beneficial effect with respect to prostate tumors. Such a result could be shown directly by measuring cytotoxic lymphocyte (CTL) generation; however, I am aware that this was not possible in these studies because the assay was not satisfactory because of the lack of an appropriate target cell for the assay.

4. The responses measured are understood in the art to be satisfactory substitutes for measuring CTLs. Thus, the proliferation of lymphocytes from two of the patients in response to contact with PSA or in response to peptides representing putative PSA epitopes is indicative of an appropriate cellular immune response. The ability of PSA or PSA derived peptides to stimulate cytokine production -- i.e., gamma interferon and IL-4 production -- from lymphocytes in these patients also indicates that the cellular response is obtained specifically with respect to PSA. The observation of the development of a positive skin test response to PSA in one patient is also consistent with these observations showing the development of cell-mediated immunity in the patients.

5. In my opinion, the results obtained in this clinical study provide evidence that the vaccines are likely to be effective in exerting a beneficial effect on patients with prostate tumors or at risk for prostate tumors.

6. The efficacy shown for the vaccine tested in the foregoing clinical studies further provides evidence that analogous vaccines based on host tissue antigen, such as prostate specific membrane antigen (PSMA) and prostate acid phosphatase (PAP) would behave in a similar manner. It is also well known that if the entire antigen is effective as a vaccine, portions of the antigen will be effective as well, especially if manipulated by art-known methods to enhance their immunogenicity, such as by coupling them to carrier.

7. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

October 10, 1996 Michael Mastrangelo, MD

Revised 12/93

CURRICULUM VITAE

NAME: Michael J. Mastrangelo, M.D. SOCIAL SECURITY NO: 210-28-9391

DATE OF BIRTH: October 3, 1938

MARITAL STATUS: Married 1964 - Ann Sunday

Children:

David M.	1965
Mark S.	1967
Audrey A.	1970

EDUCATION

Villanova University, Villanova, PA	
B.S. (Biology), Summa Cum Laude (1/696)	1956-1960
The Johns Hopkins University School of Medicine, M.D.	1960-1964

POSTGRADUATE TRAINING

Thomas Jefferson University Hospital, Philadelphia, PA

Medical Intern	1964-1965
Medical Resident	1967-1969
American Cancer Society Trainee	1968-1969
Oncology Fellow	1969-1970
Chief Medical Resident	1970-1971
Post-doctoral Fellow	1971-1972

Laboratory of R. T. Prehn, M.D.
The Institute for Cancer Research
7701 Burholme Avenue
Philadelphia, PA 19111

MILITARY SERVICE

CPT, MC, U.S. Army, Molecular Biology Branch,
Medical Laboratories, Edgewood Arsenal, MD 1965-1967

SPECIALTY CERTIFICATION

Diplomate of the American Board of Internal Medicine	1972
Certificate #37358	
Diplomate, subspecialty of Medical Oncology	1973
Certificate #37358	

LICENSURE

Maryland - D7736	1964
Pennsylvania - MD 008521-E	1965
New Jersey - MA24857	1971

HONORARY SOCIETIES

Delta Epsilon Sigma	1960
National Collegiate Who's Who	1960
Sigmi Xi	1984

Exhibit A

PROFESSIONAL SOCIETIES

College of Physicians of Philadelphia	1971
Philadelphia County Medical Society	1972-1986
Pennsylvania Medical Society	1972-1986
American Medical Association	1972-1986
American Federation for Clinical Research	1972
American Association for the Advancement of Science	1973
American Society of Clinical Oncology	1973
American College of Physicians - Member	1973
- Fellow	1975
American College of Clinical Pharmacology Fellow	1974
American Association for Cancer Research	1974
Program Committee for Immunology - Member	1979-1980
" " " " - Chairperson	1987-1988
Membership Committee	1984-1985
Gertrude Elion Award Committee	1993-1994
Society for Biological Therapy	1981-
Board of Directors	1988-1991
Chairman, Program and Publications Committee	1989-1990
President	1990-1992

PROFESSIONAL ACTIVITIES

Seminars in Oncology - Associate Editor	1974-
Eastern Cooperative Oncology Group - Member	1973-1976
Malignant Melanoma Clinical Cooperative Group - Member	1973-1977
Committee on Tumor Immunotherapy, DCBD, NCI - Member	1975-1979
American Cancer Society, Philadelphia Division	
Member, Professional Education Committee	1975-1977
Member, Board, Northeast Unit	1978-1979
American Cancer Society, National Office	
Member, Advisory Committee on Immunology and Immunotherapy	1987-1991
Philadelphia County Medical Society -	1976-1984
Member, Cancer Control Subcommittee	1976-1977
Experimental Therapeutic Study Section, NIH -	
Member	1980-1982
Chairman I + II	1982-1984
Cancer Immunology and Immunotherapy - Board of Editors	1981-1993
Subcommittee on Biological Response Modifiers of the	1978-1980
Division of Cancer Treatment's Board of Scientific Counsellors	
Biological Response Modifier Program, DCT, NCI -	
Operating Committee, Member	1980-1982
Decision Network Committee, Member	1980-1984
Journal of Biological Response Modifiers - Editoral Board	1982-1990
Journal of Immunotherapy - Editorial Board	1990-
Cancer Research - Associate Editor	1983-1994
Hybridoma - Editorial Board	1987-1992
PDQ - Extramural Board	1989-1993
The United States Pharmacopeial Convention, Inc.	
Advisory Panel on Hematologic and Neoplastic Diseases	1990-1995
Vaccine Research - Associate Editor, Tumor Vaccines	1990-

FACULTY AND APPOINTMENTS

Current -

Professor of Medicine,	1984-
Director, Division Medical Oncology	1984-1993
Member, Division Neoplastic Diseases	1993-
Jefferson Medical College 1025 Walnut Street Philadelphia, PA 19107	
Courtesy Staff	1987-
Associate Staff	1984-1987
Associate Physician (Medicine)	1977-1984
Assistant Physician (Medicine)	1972-1976
Director, Pigmented Lesion Clinic American Oncologic Hospital Central and Shelmire Avenues Philadelphia, PA	1972-1984
Consultant, Oncology Department of Medicine The Mercer Medical Center Trenton, NJ	1973-
Consultant, Oncology Division Retina Service Wills Eyes Hospital Philadelphia, PA	1974-

Prior

Instructor (Medicine)	1970-1974
Assistant Physician (Medicine) Jefferson Medical College and Hospital Philadelphia, PA 19107	1971-1974
Clinical Associate Professor (Medicine)	1977-1984
Clinical Assistant Professor (Medicine) School of Medicine Temple University Health Science Center Philadelphia, PA 19107	1974-1977
Research Physician The Institute for Cancer Research Philadelphia, PA	1972-1980
Consultant, Medical Oncology Doylestown Hospital Doylestown, PA	1976-1986
Consultant, Tumor Immunotherapy Chestnut Hill Hospital Philadelphia, PA	1973-1988

PUBLICATIONS

APERS

1. Mastrangelo, M.J., Giordano, W.P. and Johnson, R.P. Surface behavior of individual lipids similar to constituents of pulmonary surfactant. EATR 4087, April 1967.

2. Mastrangelo, M.J. and Johnson, R.P. Segmental reversibility and hysteresis of preparations similar to pulmonary surfactant. EATR 4097, May 1967.

3. Mastrangelo, M.J., Carwile, H. and Johnson, R.P. Qualitative protein composition of lung surfactant preparations. EATR 4124, August 1967.

*4. Weiss, A.J. and Mastrangelo, M.J. Phase I study of a combination of azotomycin (NSC-56654) and 5-Fluorouracil (NSC-19893) in malignant disease. Cancer Chemother Rpt. 54:109-112, 1970.

5. Mastrangelo, M.J. and Weiss, A.J. The chemotherapy of respiratory tract neoplasms. In: Cancer Chemotherapy II, I. Brodsky, S.B. Kahn, J.H. Moyer (Editors), Grune and Stratton, Inc., New York, NY, 1972, pp. 195-208.

*6. Weiss, A.J., Stambaugh, J.E., Mastrangelo, M.J., Laucius, J.F. and Bellet, R.E. A Phase I study of 5-azacytidine (NSC-102816). Cancer Chemother. Rpt. 56:413-420, 1972.

7. Mastrangelo, M.J., Sulit, H.O., Chee, D. and Engstrom, P.F. Cancer Forum: Malignant Melanoma. Penna. Med. 75:43, 1972.

*8. Mastrangelo, M.J., Grage, T. Bellet, R.E. and Weiss, A.J. A Phase I study of emetine hydrochloride (NSC-33669) in solid tumors. Cancer 31:1170-1175, 1973.

*9. Bellet, R.E., Mastrangelo, M.J., Engstrom, P.F. and Custer, R.P. Hepatotoxicity of 5-azacytidine (NSC-102816): A clinical and pathologic study. Neoplasma 20:303-310, 1973.

*10. Bellet, R.E., Mastrangelo, M.J., Dixon, L.M. and Yarbro, J.W. A Phase I study of ICRF 159 (NSC-129943) in solid tumors. Cancer Chemother. Rpt. 57:185-189, 1973.

11. Mastrangelo, M.J., Creech, R.H. and Engstrom, P.F. Cancer Forum: Early diagnosis holds promise in lung cancer. Penna. Med. 76:64, 1973.

12. Bornstein, R.S., Mastrangelo, M.J., Sulit, H.L., Chee, D.O., Yarbro, J.W., Prehn, L.M. and Prehn, R.T. Immunotherapy of melanoma with intralesional BCG. Natl. Cancer Inst. Monogr. 39:213-220, 1973.

*13. Mastrangelo, M.J., Kim, Y.H., Bornstein, R.S., Chee, D.O., Sulit, H.L., Yarbro, J.W. and Prehn, R.T. Clinical and histological correlation of melanoma regression following intralesional BCG therapy: A case report. J. Natl. Cancer Inst. 52:19-24, 1974.

*14. Bellet, R.E., Mastrangelo, M.J., Engstrom, P.F., Strawitz, J.G. and Weiss, A.J. Clinical trial with subcutaneously administered 5-Azacytidine (NSC-102816). Cancer Chemother. Rpt. 58:217-222, 1974.

* Reviewed Journal

*15. Bodurtha, A., Kim, Y.H., Laucius, J.F., Donato, R.A. and Mastrangelo, M.J. Hepatic granulomas and other hepatic lesions associated with BCG immunotherapy for cancer. Am. J. Clin. Pathol. 61:747-752, 1974.

*16. Bellet, R.E., Mastrangelo, M.J. and Dixon, L.M. Letter to the Editor: ICRF 159. Lancet 1:926, 1974.

17. Mastrangelo, M.J., Laucius, J.F. and Outzen, H.C. Fundamental concepts in tumor immunology: A brief review. Semin. Oncol. 1:291-296, 1974.

*18. Laucius, J.F., Bodurtha, A.J., Mastrangelo, M.J. and Creech, R.H. Bacillus Calmette-Guerin in the treatment of neoplastic disease. J. Reticuloendothel. Soc. 16:347-373, 1974. (Abstracted Year Book of Cancer 1976).

*19. Bodurtha, A.J., Chee, D.O., Laucius, J.F., Mastrangelo, M.J. and Prehn, R.T. Clinical and immunological significance of human melanoma cytotoxic antibody. Cancer Res. 38:189-193, 1975.

*20. Creech, R.H., Catalano, R.B., Mastrangelo, M.J. and Engstrom, P.F. Low dose cyclophosphamide, methotrexate, and 5-fluorouracil therapy of metastatic breast cancer. Cancer 35:1101-1107, 1975.

*21. Mastrangelo, M.J., Bellet, R.E., Berkelhammer, J. and Clark, W.H., Jr. Regression of pulmonary metastatic disease associated with intralesional BCG therapy of dermal melanoma metastases. Cancer 36:1305-1308, 1975. (Abstracted Year Book of Diagnostic Radiology 1977).

*22. Berkelhammer, J., Mastrangelo, M.J., Laucius, J.F., Bodurtha, A.J. and Prehn, R.T. Sequential in vitro reactivity of lymphocytes from melanoma patients receiving immunotherapy compared with the reactivity of lymphocytes from healthy donors. Int. J. Cancer 16:571-578, 1975.

*23. Sieper, W.J., Mastrangelo, M.J. and Bellet, R.E. Phase II study of adriamycin (NSC-123127) in patients with metastatic melanoma. Cancer Chemother. Rpt. 59:1181-1182, 1975.

*24. Pliskin, M.E., Mastrangelo, M.J., Brown, A.M. and Custer, R.P. Melanoma of the maxilla presenting as a gingival swelling. Oral Surg. Oral Med. Oral Pathol. 41:101-104, 1976.

*25. Mastrangelo, M.J., Sulit, H.L., Prehn, L.M., Bornstein, R.S., Yarbro, J.W. and Prehn, R.T. Intralesional BCG in the treatment of metastatic malignant melanoma. Cancer 37:684-692, 1976.

*26. Bodurtha, A.J., Berkelhammer, J., Kim, Y.H., Laucius, J.F. and Mastrangelo, M.J. A clinical, histological and immunological study of a case of metastatic malignant melanoma undergoing spontaneous remission. Cancer 37:735-742, 1976.

*27. Ainsworth, A.M., Clark, W.H., Jr., Mastrangelo, M.J. and Conger, K.B. Primary malignant melanoma of the urinary bladder. Cancer 37:1928-1936, 1976.

*Reviewed Journal

28. Bellet, R.E. and Mastrangelo, M.J. Investigational new drugs. In: Oncologic Medicine, P.F. Engstrom, A.I. Sutnick (Editors), University Park Press, Baltimore, MD, 1976, pp. 237-245.

*29. Mastrangelo, M.J., Bellet, R.E., Laucius, J.F. and Berkelhammer, J. Immunotherapy of malignant melanoma. A Review. In: Oncologic Medicine, P.F. Engstrom, A.I. Sutnick (Editors), University Park Press, Baltimore, MD, 1976, pp. 71-93.

*30. Pliskin, M.E., Mastrangelo, M.J., Bellet, R.E. and Berkelhammer, J. BCG immunotherapy of a mucous membrane malignant melanoma (a case report). Oral Surg. Oral Med. Oral Pathol. 42:73-79, 1976.

*31. Mastrangelo, M.J., Berd, D. and Bellet, R.E. Critical review of previously reported clinical trials of cancer immunotherapy with non-specific immunostimulant. Ann. N.Y. Acad. Sci. 277:94-123, 1976.

*32. Bellet, R.E., Mastrangelo, M.J., Laucius, J.F. and Bodurtha, A.J. A randomized prospective trial of DTIC (NSC-45388) alone versus BCNU (NSC-409962) plus vincristine (NSC-67574) in the treatment of metastatic malignant melanoma. Cancer Treat. Rpt. 60:595-600, 1976.

33. Mastrangelo, M.J., Berd, D. and Bellet, R.E. Review of immunotherapeutic studies on cancer patients. In: Immuno-Cancerology in Solid Tumors, M. Martin, L. Dionne (Editors), Stratton Intercontinental Medical Book Corporation, New York, NY, 1976, pp. 155-170.

*34. Bellet, R.E., Catalano, R.B., Danna, V.G., Berkelhammer, J. and Mastrangelo, M.J. A study of antitumor (Phase II) and immunosuppressive effects of ICRF-159 (NSC-129943) in patients with metastatic melanoma. J. Clin. Pharm. 16:433-438, 1976.

*35. Bellet, R.E., Engstrom, P.F., Catalano, R.B., Creech, R.H. and Mastrangelo, M.J. Phase II study of ICRF-159 (NSC-129943) in patients with metastatic colorectal carcinoma previously exposed to systemic chemotherapy. Cancer Treat. Rpt. 60:1395-1397, 1976.

36. Clark, W.H., Jr., Mastrangelo, M.J., Ainsworth, A.M., Berd, D., Bellet, R.E. and Bernardino, E.A. Current concepts of the biology of human cutaneous malignant melanoma. Adv. Cancer Res. 24:267-338, 1977.

*37. Berkelhammer, J., Mastrangelo, M.J. and Prehn, R.T. Effect of treatment with dimethyl triazeno imidazole carboxamide (DTIC, NSC-45388) or 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU, NSC-409962) plus vincristine (NSC-67564) on lymphocyte reactivity of melanoma patients. Cancer Immunol. Immunother. 2:119-125, 1977.

*38. Laucius, J.F., Patel, Y.A., Koons, L.S., Bellet, R.E. and Mastrangelo, M.J. A Phase II evaluation of Bacillus Calmette-Guerin plus megestrol acetate in patients with metastatic renal adenocarcinoma. Med. Pediatr. Oncol. 3:237-242, 1977.

*39. Bellet, R.E., Vaisman, I., Mastrangelo, M.J. and Lustbader, E. Multiple primary malignancies in patients with cutaneous melanoma. Cancer 40:1974-1981, 1977.

* Reviewed Journal

*40. Laucius, J.F., Bodurtha, A.J., Mastrangelo, M.J. and Bellet, R.E. A Phase II study of autologous irradiated tumor cells plus BCG in patients with metastatic malignant melanoma. Cancer 40:2091-2093, 1977.

41. Mastrangelo, M.J., Bellet, R.E., Berd, D., and Lustbader, E. A randomized prospective trial comparing methyl-CCNU + vincristine to methyl-CCNU + vincristine + BCG + allogeneic tumor cells in patients with metastatic malignant melanoma. In: Immunotherapy of Cancer: Current Status of Trials in Man, W. Terry and D. Windhorst (Editors), Progress in Cancer Research and Therapy, Vol. 6, Raven Press, New York, NY, 1978, pp. 95-102.

42. Mastrangelo, M.J., Clark, W.H., Jr., Bellet, R.E. and Berd, D. Cutaneous malignant melanoma: Diagnosis prognosis and conventional therapy. In: Immunotherapy of Cancer: Current Status of Trials in Man, W. Terry, D. Windhorst (Editors), Progress in Cancer Research and Therapy, Vol. 6, Raven Press, New York, NY, 1978, pp. 1-17.

43. Engstrom, P.F., Paul, A.R., Catalano, R.B., Mastrangelo, M.J. and Creech, R.H. Fluorouracil versus fluorouracil + BCG in colorectal adenocarcinoma. In: Immunotherapy of Cancer: Current Status of Trials in Man, W. Terry, D. Windhorst (Editors), Progress in Cancer Research and Therapy, Vol. 6, Raven Press, New York, NY, 1978, pp. 587-596.

*44. Bellet, R.E., Catalano, R.B., Mastrangelo, M.J. and Berd, D. Phase II study of subcutaneously administered 5-azacytidine (NSC-102816) in patients with metastatic malignant melanoma. Med. Pediatr. Oncol. 4:11-15, 1978.

45. Greene, M.H., Reimer, R.R., Clark, W.H., Jr. and Mastrangelo, M.J. Precursor lesions in familial melanoma. Semin. Oncol. 5:85-87, 1978.

*46. Bellet, R.E., Catalano, R.B., Mastrangelo, M.J., Berd, D. and Koons, L.S. Phase II trial of VM-26 (NSC-122819) in patients with metastatic melanoma. Cancer Treat. Rpt. 62:445-447, 1978.

*47. Clark, W.H., Jr., Reimer, R.R., Green, M., Ainsworth, A.M. and Mastrangelo, M.J. Origin of familial malignant melanoma from heritable melanocytic lesions. The B-K mole syndrome. Arch. Derm. 114:732-738, 1978.

48. Berkelhammer, J., Mastrangelo, M.J., Bellet, R.E., Prehn, R.T. and Thibault, L.H. Failure of lymphocyte microcytoxicity to distinguish relapsers from non-relapse in melanoma patients receiving postsurgical adjuvant chemotherapy. Eur. J. Cancer 14:793-798, 1978.

49. Mastrangelo, M.J., Berd, D. and Bellet, R.E. Limitations, obstacles and controversies in the optimal development of immunotherapy. In: Immunotherapy of Human Cancer, E. Hersh, J. Sinkovics (Editors), Raven Press, New York, NY, 1978, pp. 375-394.

50. Bellet, R.E., Mastrangelo, M.J., Berd, D. and Lustbader, E. Melanoma chemotherapy. In: Cancer Chemotherapy III, I Brodsky, S.B. Kahn, J.F. Conroy (Editors), Grune and Stratton, Inc., New York, 1978, pp. 225-242.

51. Mastrangelo, M.J. and Bellet, R.E. Immunotherapy of melanoma. In: Clinical Therapeutics, D.T. Lowenthal, D.A. Major II, (Editors), Grune and Stratton, Inc., New York, 1978, pp. 281-291.

* Reviewed Journal

*52. Bellet, R.E., Catalano, R.B., Mastrangelo, M.J. and Berd, D. A positive Phase II trial of dibromodulcitol in patients with metastatic melanoma refractory to DTIC and nitrosourea. Cancer Treat. Rpt. 62:2095-2099, 1978.

53. Bellet, R.E., Mastrangelo, M.J. and Berd, D. Chemotherapy of metastatic malignant melanoma. In: Human Malignant Melanoma, Grune and Stratton, Inc., New York, 1979, pp. 355-416.

54. Vaisman, I., Mastrangelo, M.J., Bellet, R.E. and Lustbader, E. Primary cutaneous melanoma and coexisting malignant neoplasms. In: Human Malignant Melanoma, Grune and Stratton, Inc., New York, 1979, pp. 243-260.

55. Mastrangelo, M.J., Bellet, R.E. and Berd, D. Immunology and immunotherapy of malignant melanoma. In: Human Malignant Melanoma, Grune and Stratton, Inc., New York, 1979, pp. 355-416.

56. Mastrangelo, M.J., Bellet, R.E. and Berd, D. Adjuvant therapy. In: Human Malignant Melanoma, Grune and Stratton, Inc., New York, 1979, pp. 309-324.

57. Mastrangelo, M.J., Bellet, R.E. and Berd, D. Prognostic Factors. In: Human Malignant Melanoma, Grune and Stratton, Inc., New York, 1979, pp. 273-281.

58. Berd, D., Mastrangelo, M.J. and Bellet, R.E. Metastatic uveal melanoma. In: Human Malignant Melanoma, Grune and Stratton, Inc., New York, 1979, pp. 489-496.

59. Laucius, J.F. and Mastrangelo, M.J. Cutaneous depigmentary phenomena in patients with malignant melanoma. In: Human Malignant Melanoma, Grune and Stratton, Inc., New York, 1979, pp. 209-226.

*60. Berkelhammer, J., Mastrangelo, M.J., Bellet, R.E., Berd, D. and Prehn, R.T. Chemoimmunotherapy increases the lymphocyte reactivity of melanoma patients. Eur. J. Cancer 15:197-204. 1979.

*61. Mastrangelo, M.J., Bellet, R.E. and Berd, D. A Phase III comparison of methyl-CCNU + vincristine with or without BCG + allogeneic tumor cells in metastatic melanoma. Cancer Immunol. Immunother. 6:231-236, 1979.

*62. Goepp, C.E., Mastrangelo, M.J., Patel, Y.A. and Clark, W.H., Jr. Cutaneous malignant melanoma in a patient with neurofibromatosis. Arch. Dermatol. 115:864-866, 1979.

*63. Berd, D., Wilson, E.J., Bellet, R.E. and Mastrangelo, M.J. The effect of methyl-CCNU adjuvant therapy on immune responses of patients with malignant melanoma. Cancer Res. 39:4472-4476, 1979.

*64. Bellet, R.E., Danna, V., Mastrangelo, M.J. and Berd, D. Evaluation of a "nude" mouse-human tumor panel as a predictive secondary screen for cancer chemotherapeutic agents. J. Natl. Cancer Inst. 63:1185-1188, 1979.

65. Tems-Reines, S.J. and Mastrangelo, M.J. In: Clinical Immunotheapy, A. F. LoBuglio (Editor), Marcel Dekker, Inc., NY, 1980, pp. 7-29.

* Reviewed Journal

*66. Augsburger, J.J., Shields, J.A., Mastrangelo, M.J. and Frank, P.F. Diffuse primary malignant melanoma of the choroid arising in a patient with prior cutaneous malignant melanoma. Arch. Ophthalmol. 98:1261-1264, 1980.

*67. Herlyn, M., Clark, W.H., Jr., Mastrangelo, M.J., Guerry, D. IV, Elder, D.E., LaRossa, D., Hamilton, R., Bondi, E.M., Tuthill, R., Steplewski, Z. and Koprowski, H. Specific immunoreactivity of monoclonal anti-melanoma antibodies. Cancer Res. 40:3602-3609, 1980.

68. Mastrangelo, M.J., Hersh, E. and Chirigos, M. Augmenting agents in cancer therapy: Workshop summation. In: Augmenting Agents in Cancer, E. Hersh, M. Chirigos, M. Mastrangelo (Editors), Raven Press, New York, NY, 1981, pp. 553-564.

*69. Berd, D. and Mastrangelo, M.J. Differential sensitivity of two murine leukemia sublines to cytolysis by Corynebacterium parvum-activated macrophages. Br. J. Cancer 44:819-827, 1981.

70. Bellet, R.E. and Mastrangelo, M.J. Malignant melanoma: Investigations in the "nude mouse." In: The Nude Mouse in Experimental and Clinical Research, Vol. II, J. Fogh, B. Giovanella (Editors), Academic Press, New York, NY, 1982, pp. 511-519.

71. Chirigos, M. and Mastrangelo, M.J. Immunorestoration by chemicals. In: Immunologic Aspects of Cancer Therapeutics, E. Mihich (Editor), John Wiley and Sons, Inc., NY, 1982, pp. 191-239.

72. Mastrangelo, M.J., Rosenberg, S.A., Baker, A. and Katz, H. Cutaneous melanoma. In: Cancer Principles and Practices of Oncology, V.T. DeVita, S. Hellerman, S. Rosenberg (Editors), J.B. Lippincott, Co., Philadelphia, PA, 1982, pp. 1124-1187.

73. Mastrangelo, M.J. and Berd, D. Immunotherapy with microbial products. In: Immunological Aspects of Cancer Therapeutics, E. Mihich (Editor), John Wiley and Sons, Inc., NY, 1982, pp. 75-105.

*74. Berd, D., Mastrangelo, M.J., Engstrom, P.F., Paul, A. and Maguire, H. Augmentation of the human immune response by cyclophosphamide. Cancer Res. 42:4862-4866, 1982.

75. Bellet, R.E., Mastrangelo, M.J., Berd, D. and Maguire, H.C. Primary cutaneous melanoma. In: Concepts in Cancer Medicine, S.B. Kahn, R. Love, R. Chakravorty, C.W. Sherman (Editors), Grune and Stratton, Inc., New York, 1982, Chapter 9, pp. 545-555.

76. Bellet, R.E., Danna, V., Mastrangelo, M.J., Eaton, G.J. and Berd, D. Evaluation of the response of a panel of human melanoma tissue-cultured cell lines xenografted in nude mice to four anticancer drugs of known clinical activity. Proc. 3rd Int. Workshop on Nude Mice, Gustav Fischer, New York, NY, 1982, pp. 649-656.

*77. Donoso, L.A., Nagy, R.M., Brockman, R.J., Augsburger, J.J., Shields, J.A., Berd, D. and Mastrangelo, M.J. Metastatic uveal melanoma. Hepatic cell-surface enzymes, isoenzymes and serum sialic acid levels in early metastatic disease. Arch. Ophthalmol. 101:791-794, 1983.

* Reviewed Journal

*78. Berd, D., Maguire, H.C. and Mastrangelo, M.J. Impairment of concanavalin A-inducible suppressor activity following administration of cyclophosphamide to patients with advanced cancer. Cancer Res. 44:1275-1280, 1984.

*79. Mastrangelo, M.J., Berd, D. and Maguire, H.C. The current condition and prognosis of tumor immunotherapy: A second opinion. Cancer Treat. Rpt. 68:207-21[illegible], 1984.

80. Berd, D., Maguire, H.C. and Mastrangelo, M.J. Immunopotentiation by cyclophosphamide and other cytotoxic agents. In: Immunomodulationg Agents, R. Fenichel (Editor), Marcel Dekker, 1984, pp 39-62.

81. Berd, D., Maguire, H.C. and Mastrangelo, M.J. Potentiation of human cell-mediated and humoral immunity by low dose cyclophosphamide. Cancer Res. 44:5439-[illegible], 1984.

*82. Donoso, L.A., Berd, D., Augsburger, J.J., Mastrangelo, M.J. and Shields, Metastatic uveal melanoma: Pretherapy serum liver enzyme and liver scan abnormalities Arch. Ophtahlmol. 103:796-798, 1985.

*83. Goldman, L.I., Elder, D.E., Mastrangelo, M.J., Clark, W.H. and Stennett, J. Assessment of survival with metastatic malignant melanomas. Surg. Gynecol. Obstet. 162:199-203, 1986.

*84. Berd, D., Maguire, H.C. and Mastrangelo, M.J. Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphasmide. Cancer Res. 46:2572-2577, 1986.

85. Mastrangelo, M.J., Berd, D. and Maguire, H., Jr. The immunoaugmenting effects of cancer chemotherapeutic agents. Semin. Oncol. 13:186-194, 1986.

*86. Slovin, S.F., Lackman, R.D., Ferrone, S., Kiely, P.E. and Mastrangelo, M.J. Cellular immune response to human sarcomas: Cytotoxic T cell clones reactive with autologous sarcomas. I. Development, phenotype and specificity. J. Immunol. 137:3042-3048, 1986.

*87. McClay, E., Lusch, C.J. and Mastrangelo, M.J. Allergy induced hepatic toxicity associated with DTIC (Dacarbazine). Cancer Treat. Rep. 71:219-220, 1987.

*88. McClay, E., Mastrangelo, M.J., Bellet, R.E. and Berd, D. Combination chemo/hormonal therapy in the treatment of malignant melanoma. Cancer Treat. Rep. 71:465-469, 1987.

*89. Slovin, S.F., Lackman, R.D., Mastrangelo, M.J. and the Thomas Jefferson University Sarcoma Study Group. HLA-A2 in sarcomas: An immunologic perspective. Transplantation 43:923-925, 1987.

*90. Berd, D. and Mastrangelo, M.J. Depletion of suppressor T lymphocytes by administration of a murine monoclonal antibody. Cancer Res. 47:2727-2732, 1987.

91. Mastrangelo, M.J. and Berd, D. Control of disseminated melanoma with intralesional immunotherapy. In: Cutaneous Melanoma. Status of Knowledge and Future Perspective U. Veronesi, N. Cascinelli, M. Santinami (Editors), Academic Press, 1987, pp. 643-648.

* Reviewed Journal

*92. Berd, D. and Mastrangelo, M.J. Effect of low dose cyclophosphamide on the immune system of cancer patients: Reduction of T suppressor function without depletion of the CD8+ subset. Cancer Res. 47:3317-3321, 1987. (Abstracted Year Book of Cancer 1988).

*93. Berd, D. and Mastrangelo, M.J. Elimination of immune suppressor mechanisms in humans by oxazaphosphorines. Meth. Find. Exp. Clin. Pharmacol. 9:569-[illegible], 1987.

*94. Berd, D. and Mastrangelo, M.J. Effect of low dose cyclophosphamide on the immune system of cancer patients: Depletion of CD4+ 2H4+ suppressor-inducer T cells. Cancer Res. 48:1671-1675, 1988.

*95. Berd, D. and Mastrangelo, M.J. Active immunotherapy of human melanoma exploiting the immunopotentiating effects of cyclophosphamide. Cancer Investigation [illegible]:337-349, 1988.

*96. McClay, E.J., Mastrangelo, M.J., Berd, D. and Bellet, R.E. Letter to the Editor: Hypercoagulable state secondary to tumor lysis. N. Engl. J. Med. 319:[illegible] 1988.

97. McClay, E.J. and Mastrangelo, M.J. Systemic chemotherapy for metastatic melanoma. Semin. Oncol. 15:569-577, 1988.

98. Mastrangelo, M.J., Schultz, S., Kane, M. and Berd, D. Newer immunologic approaches to the treatment of patients with melanoma. Semin. Oncol. 15:578-588, 1988.

99. Mastrangelo, M.J. Recent advances in the medical management of metastatic melanoma. Mediguide Oncol. 9:1-6, 1989.

100. Schultz, S. and Mastrangelo, M.J. The pathophysiology and etiology of malignant melanoma. Semin. Oncol. 16 (Suppl 1):27-33, 1989.

101. Harris, D.T. and Mastrangelo, M.J. Serotherapy of cancer. Semin. Onc 16:180-198, 1989.

*102. McClay, E.J., Mastrangelo, M.J., Sprandio, J.D., Bellet, R.E., and Berd, D. The importance of tamoxifen to a cisplatin containing regimen in the treatment of metastatic melanoma. Cancer 63:1292-1295, 1989.

*103. Ehrke, M.J., Mihich, E., Berd, D. and Mastrangelo, M.J. Effects of anticancer drugs on the immune system in man. Semin. Oncol. 16:230-253, 1989.

*104. Turner, B.J., Siatowski, R.M., Augsburger, J.J., Shields, J.A., Lustbader E. and Mastrangelo, M.J. Cancers in uveal melanoma patients and their families: Implication for the genesis of this tumor. Am. J. Ophthal. 107:601-608, 1989.

105. Mastrangelo, M.J. and Berd, D. Immunoregulation and active specific immunization in cancer treatment. In: Human Melanoma - Immunology, Diagnostics and Therapy, S. Ferrone (Editor), Springer Verlag, New York, 1989, pp. 497-512.

*106. Berd, D., Herlyn, M., Koprowski, H. and Mastrangelo, M.J. Flow cytometric determination of the frequency and heterogeneity of expression of human melanoma-associated antigens. Cancer Res. 49:6840-6844, 1989.

* Reviewed Journal

*107. Cardi G., Mastrangelo, M.J. and Berd, D. Depletion of T cells with the CD4+CD45R + phenotype in lymphocytes that infiltrate subcutaneous metastases of human melanoma. Cancer Res. 49:6562-6565, 1989.

*108. Schultz, S., Kane, M., Roush, R., Miller, V., Berd, D., Goldman, L. and Mastrangelo M.J. Time to recurrence varies inversely with thickness in clinical Stage I cutaneous melanoma. Surg. Gynecol. Obstet. 171:393-397, 1990.

*109. Berd, D., Maguire, H.C., Jr., Mc Cue, P. and Mastrangelo, M.J. Immunotherapy of metastatic melanoma with an autologous tumor cell vaccine: Clinical and Immunological results in 64 patients. J. Clin. Oncol. 8:1858-1867, 1990.

*110. McLean, I.W., Berd, D., Mastrangelo, M.J., Shields, J.A., Davidorf, F.H., Grever, M., Makley, T.A. and Gamel, J.W. A randomized study of methanol extraction residue of Bacille Calmette-Guerin as postsurgical adjuvant therapy of uveal melanoma. Am. J. Ophthal. 110:522-526, 1990.

*111. Slovin, S.F., Maguire, H.C., Jr., Lackman, R.D. and Mastrangelo, M.J. The role of autologous tumor cells in preventing lymphokine-activated killer cell induction in vitro. Cancer 66:2541-2546, 1990.

112. Mastrangelo, M.J., Bellet, R.E. and Berd D. Aggressive chemotherapy for melanoma. PPO Updates 5 (May):1-11, 1991.

113. Harris, D.T. and Mastrangelo, M.J.: Theory and application of early systemic therapy. Semin. Oncol. 18:493-503, 1991.

114. Berd, D., Murphy, G., Maguire, H.C., Jr. and Mastrangelo, M.J. Immunization with haptenized, autologous tumor cells induces inflammation of human melanoma metastases. Cancer Res 51:2731-2734, 1991.

*115. Herlyn, D., Benden, A., Kane, M., Somasundaram, R., Zaloudik, J., Sperlagh, M., Marks, G., Hart, E., Ralph C., Wettendorff, M. and Mastrangelo, M.J. Anti-idiotype cancer vaccines: Preclinical and clinical studies. In Vivo 5:615-624, 1991.

116. Mastrangelo, M.J., Bellet, R.E., Kane, M.J. and Berd D. Melanoma. In: Chemotherapy Source Book, M. Perry (Editor), William and Wilkins, Baltimore 1992, pp 886-907.

*117. McClay, E.F., Mastrangelo, M.J., Berd, D., and Bellet, R.E. Effective combination chemo/hormonal therapy for malignant melanoma: Experience with three consecutive trials. Int J Cancer 50:553-556, 1992.

*118. Fishbein, G.E., McClay, E., Berd, D., Mastrangelo, M.J.: A post surgical adjuvant trial of CEA immunization in patients with Dukes C and D colorectal cancer A pilot study. Vaccine Res 1:123-128, 1992.

119. Mastrangelo, M.J., Harris, D.T.: Cutaneous Melanoma. In: Current Therapy in Oncology. J. Niederheuber (Editor), B. C. Decker, St. Louis, 1993, pp 132-138

* Reviewed Journal

*120. McLaughlin, C., Maguire, H.C. Jr. and Mastrangelo, M.J. Case Report: The natural history of a superficial spreading melanoma. Int. J. Dermatol. 32:293-296,1993.

*121. Berd, D., Maguire, H.C. Jr., Mastrangelo, M.J. Treatment of human melanoma with a hapten-modified autologous vaccine. Ann. N.Y. Acad. Sci. 690:147-152, 1993.

*122. Herlyn, D., Zaloudik, J., Somasundaram, R., Jacob, L., Benden, A. and Mastrangelo, M.J. Anti-idiotype vaccine in colorectal cancer patients. Hybridoma 12:515-520, 1993.

123. Mastrangelo, M.J. Controlled studies in chemotherapy for advanced melanoma. In: Malignant Melanoma: The approach of the surgical oncologist, F.J. Lejeune, P.K. Chaudhuri, T.K. Das Gupta (Editors), McGraw-Hill, Inc., New York, NY 1994, pp. 295-301.

124. Herlyn, D., Harris, D., Zaloudik, J., Sperlagh, M., Maruyama, H., Jacob, L., Kieny, M-P, Scheck, S., Somasundaram, R., Hart, E., Erte, H. and Mastrangelo, M.J. Immunomodulatory activity of monoclonal anti-idiotypic antibody to anti-colorectal carcinoma antibody CO17-1A in animals and in patients. J. Immunother (accepted 1/94).

*125. Berd, D., Maguire, H.C., Jr., Mastrangelo, M.J. and Murphy, G.P. Activation markers on T cells infiltrating melanoma metastases after therapy with dinitrophenyl conjugated vaccine (submitted 8/93).

*126. Somasundaram, R., Zaloudik, J., Jacob, L., Benden, A., Sperlagh, M., Hart, E., Marks, G., Kane, M., Mastrangelo, M., Herlyn, D. Induction of B- and T-cell immunity in colon cancer patients by anti-idiotypic antibody. (Submitted 2/93).

*127. Sato, T., Maguire, H.C., Jr., Mastrangelo, M.J. and Berd, D. Human immune response to DNP-modified autologous cells after treatment with a DNP-conjugated vaccine. J Immunol (submitted 2/94).

*128. Lee, S.S., Eisenlohr, L.C., McCue, P.A., Mastrangelo, M.J. and Lattime, E.C. Intravesical gene therapy: In-vivo gene transfer using recombinant vaccinia virus vectors. Cancer Research (submitted 2/94).

129. Mastrangelo, M.J., Maguire H.C., Jr., Lattime, E.C. and Berd, D. Whole cell vaccines, In: Biological Therapy of Cancer, 2nd Edition, DaVita, V.T., Hellman, S., Rosenberg, S.A. (Editors), Lippincott, Philadelphia (submitted 2/94).

*130. Berd, D., Wiebe, V., Mastrangelo, M.J., Bellet, R.E. and DeGregorio, M.W. Short course, high dose tamoxifen with cytotoxic chemotherapy for metastatic melanomas. Int J Cancer (submitted 9/91).

* Reviewed Journal

ABSTRACTS

A1. Mastrangelo, M.J., Giordano, W.P. and Johnson, R.P. Surface behavior of individual lipids similar to pulmonary surfactant. Physiologist 9:240, 1966.

A2. Mastrangelo, M.J., Bornstein, R.S. and Yarbro, J.W. A clinical trial of adriamycin in adult solid tumors. Clin. Res. 19:738, 1971.

A3. Mastrangelo, M.J., Bornstein, R.S., Sulit, H.L., Chee, D.O., Yarbro, J.W. and Prehn, R.T. Immunotherapy of malignant. Ann. Intern. Med. 76:877-878, 1972 (Abstract #80).

A4. Sulit, H.L., Chee, D.O., Mastrangelo, M.J., Engstrom, P.F., Bornstein, R.S., Prehn, R.T. and Yarbro, J.W. In vitro assays of cellular and humoral immunity during clinical trials of immunotherapy in human melanoma. Proc. Am. Assoc. Cancer Res. 13:74, 1972 (Abstract #294).

A5. Bellet, R.E., Mastrangelo, M.J., Engstrom, P.F., Bornstein, R.S., Strawitz, J.G., Yarbro, J.W. and Weiss, A.J. Phase I study of subcutaneous 5-azacytidine in solid tumors. Clin. Res. 20:562, 1972.

A6. Bellet, R.E., Mastrangelo, M.J., Bornstein, R.S., Engstrom, P.F. and Gerstley, B.J. A Phase I study of ICRP 159. Clin. Res. 20:884, 1972.

A7. Mastrangelo, M.J., Kim, Y.H., Bornstein, R.S., Chee, D.O., Sulit, H.L. and Yarbro, J.W. Clinico-pathological correlation of BCG-induced melanoma regression. Proc. Am. Assoc. Cancer Res. 14:65, 1973 (Abstract #257).

A8. Mastrangelo, M.J., Bornstein, R.S., Sulit, H.L., Chee, D.O., Prehn, R.T. and Yarbro, J.W. An immunological approach to the treatment of malignant melanoma. J. Dent. Res. 52:59, 1973 (Abstract #4).

A9. Bodurtha, A.J., Laucius, J.F., Mastrangelo, M.J., Prehn, L.M. and Prehn, R.T. An immunological approach to the treatment of malignant melanoma. Ann. R. Coll. Phys. Surg. Can. 7:46, 1974 (Abstract #128).

A10. Laucius, J.F., Bodurtha, A.J., Berkelhammer, J., Prehn, L.M., Prehn, R.T. and Mastrangelo, M.J. Intradermal injection of autochthonous irradiated tumor cells plus BCG in the treatment of metastatic malignant melanoma. Proc. Am. Soc. Clin. Oncol. 15:171, 1974 (Abstract #749).

A11. Bodurtha, A.J., Chee, D.O., Laucius, J.F., Mastrangelo, M.J. and Prehn, R.T. Clinical and immunological significance of human melanoma cytotoxic antibody. Proc. Am. Assoc. Cancer Res. 15:63, 1974 (Abstract #251).

A12. Creech, R., Catalano, R., Mastrangelo, M.J. and Engstrom, P.F. An effective low-dose three-drug regimen for metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 14:179, 1974 (Abstract #783).

A13. Laucius, J.F., Bodurtha, A.J., Creech, R. and Mastrangelo, M.J. Randomized prospective trial comparing BCNU plus vincristine (VCR) versus imidazole carboxamide (DTIC) in patients with metastatic malignant melanoma. Proc. XI Int. Cancer Congr. 3:540, 1974.

A14. Berkelhammer, J., Mastrangelo, M.J. and Prehn, R.T. Sequential in vitro reactivity of lymphocytes from melanoma patients receiving immunotherapy compared with the reactivity of lymphocytes from healthy donors. Proc. Am. Assoc. Cancer Res. 16:94, 1975 (Abstract #375).

A15. Engstrom, P.F., Catalano, R.B., Creech, R.H. and Mastrangelo, M.J. Chemoimmunotherapy of colorectal carcinoma with 5-FU + BCG. Proc. Am. Soc. Clin, Oncol. 16:234, 1975 (Abstract #1052).

A16. Bellet, R.E., Mastrangelo, M.J., Creech, R.H. and Engstrom, P.F. Phase II study of ICRF-159 (NSC-129943) in human solid tumors. Proc. Am. Soc. Clin. Oncol. 16:224, 1975 (Abstract #1015).

A17. Koons, L.S., Bellet, R.E. and Mastrangelo, M.J. Piperazinedione (NSC-135758) chemotherapy for advanced squamous cell carcinoma of the lung. Proc. Am. Soc. Clin. Oncol. 18:299, 1977 (Abstract #C-132).

A18. Bellet, R.E., Mastrangelo, M.J., Berd, D. and Lustbader, E. Randomized prospective Phase III trial of methyl-CCNU (NSC-95441) alone versus methyl-CCNU + vincristine (NSC-62574) in the treatment of patients with metastatic malignant melanoma. Proc. Am. Soc. Clin. Oncol. 18:284, 1977 (Abstract #C-69).

A19. Berd, D., Wilson, E., Bellet, R.E. and Mastrangelo, M.J. Methyl-CCNU adjuvant chemotherapy of malignant melanoma is not immunosuppressive. Am. Soc. Clin. Oncol. 19:349, 1978 (Abstract #C-171).

A20. Mastrangelo, M.J., Bellet, R.E. and Berd, D. A randomized prospective trial comparing methyl-CCNU + vincristine with methyl-CCNU + vincristine + BCG + allogeneic tumor cells in patients with metastatic malignant melanoma. Am. Soc. Clin. Oncol. 19:319, 1978 (Abstract #C-52).

A21. Bellet, R.E., Mastrangelo, M.J. and Berd, D. Phase II study of dibromodulcitol in patients with metastatic malignant melanoma. Proc. Am. Assoc. Cancer Res. 19:342, 1978 (Abstract #C-141).

A22. Bellet, R.E., Mastrangelo, M.J., Berd, D. and Danna, V. Secondary animal tumor screening of chemotherapeutic agents utilizing a human melanoma-nude mouse panel. Proc. Am. Assoc. Cancer Res. 19:15, 1978 (Abstract #C-58).

A23. Maguire, H., Berd, D., Biermann, W. and Mastrangelo, M.J. Increased immunological reactivity in patients treated with cyclophosphamide (Cy). Proc. Am. Assoc. Cancer Res. 21:203, 1980 (Abstract #814).

A24. Maguire, H., Berd, D., Engstrom, P., Paul, A. and Mastrangelo, M.J. Cyclophosphamide (Cy) increases the acquisition of T-cell immunity in patients with melanoma and colorectal cancer. Proc. Am. Assoc. Cancer Res. 22:279, 1981 (Abstract #1106).

A25. Berd, D., Parker, G., Shields, J., Morris, M. and Mastrangelo, M.J. Autologous mixed lymphocyte-tumor cell (AMLTC) response in primary choroidal melanoma. Proc. Am. Assoc. Cancer Res. 22:322, 1981 (Abstract #1279).

A26. Berd, D., Danna, V., Maguire, H. and Mastrangelo, M.J. Selective impairment of suppressor T cell function after administration of cyclophosphamide (Cy). Proc. Am. Assoc. Cancer Res. 23:279, 1981 (Abstract #1104).

A27. Mastrangelo, M.J. and Berd D. Current status of biological response modifiers therapy of human cancer. Proc. XIII Inst. Cancer Congr. p. 9, 1982 (Abstract #40).

A28. Berd, D., Maguire, H. and Mastrangelo, M. Augmentation of delayed type hypersensitivity (DTH) to tumor-associated antigens by treatment with autologous tumor cell vaccine preceded by cyclophosphamide (Cy). Proc. Am. Assoc. Cancer Res. 2:56, 1983 (Abstract #C-217).

A29. Berd, D., Danna, V., Maguire, H.C. and Mastrangelo, M. Reduction of Con A-inducible suppressor T cell activity after amdinistration of cyclophosphamide (Cy). Proc. Am. Assoc. Cancer Res. 24:207, 1983 (Abstract #816).

A30. Berd, D., Danna, V., Maguire, H.C. and Mastrangelo, M. Cyclophosphamide (Cy) augments the development of delayed type hypersensitivity (DTH) to autologous human melanoma cells. Proc. Am. Soc. Clin. Oncol. 3:55, 1984 (Abstract #C-213).

A31. Berd, D., Golden, M.H., Maguire, H.C. and Mastrangelo, M.J. Augmentation of cell-mediated and humoral immunity to a primary antigen by low dose cyclophosphamide (Cy) in patients with advanced cancer. Proc. Am. Assoc. Cancer Res. 25:273, 1984 (Abstract #939).

A32. Berd, D., Golden, M.H., Maguire, H.C. and Mastrangelo, M.J. Comparison of effects of low dose versus high dose cyclophosphamide (Cy) on peripheral blood lymphocyte (PBL) composition and function. Proc. Am. Assoc. Cancer Res. 26:271, 1985 (Abstract #1067).

A33. Berd, D., Golden M.H. and Mastrangelo, M.J. In vivo depletion of T-suppressor lymphocytes by administration of the monoclonal antibody anti-Leu 2a. Proc. Am. Assoc. Cancer Res. 27:311, 1986 (Abstract #1232).

A34. Slovin, S.F., Lackman, R.D., Ferrone, S., McClay, E.F., Weiss, A.J. and Mastrangelo, M.J. Analysis of cellular immune response to sarcoma using cytotoxic T cell clones. Proc. Am. Assoc. Cancer Res. 27:360, 1986 (Abstract #1428).

A35. McClay, E., Mastrangelo, M., Bellet, R. and Berd, D. An effective chemo/hormonal therapy regimen for the treatment of disseminated malignant melanoma. Proc. Am. Soc. Clin. Oncol. 6:208, 1987 (Abstract #821).

A36. Berd, D., Golden, M.H., Clark, C., Hart, E. and Mastrangelo, M.J. Selective depletion of CD4+, 2H4+ suppressor-inducer T cells in patients treated with cyclophosphamide (Cy) and melanoma cell vaccine. Proc. Am. Assoc. Cancer Res. 28:376, 1987 (Abstract #1490).

A37. Berd, D., Clark, C., Hart, E. and Mastrangelo, M.J. An unusual pattern of tumor regression in melanoma patients treated with cyclophosphamide (Cy) + autologous tumor cell vaccine. Proc. Am. Assoc. Cancer Res. 29:408, 1988 (Abstract #1626).

Slovin, S.F., Maguire, H.C., Jr., Lackman, R.D. and Mastrangelo, M.J. The role of "educator" tumor cells in restricting polyspecificity of killer cells. Proc. Am. Assoc. Cancer Res. 29:436, 1988 (Abstract #1735).

A39. McClay, E., Sprandio, J., Mastrangelo, M., Bellet, R.E. and Berd, D. Importance of tamoxifen to a combination chemotherapy regimen for melanoma. Proc. Am. Soc. Clin. Oncol. 7:251, 1988 (Abstract #971).

A40. Schultz, S., Kane, M., Roush, R., Miller, V., Berd, D., Goldman, L. and Mastrangelo, M.J. Inverse relationship of tumor thickness and time to recurrence in patients with clinical Stage I cutaneous melanoma. Proc. Am. Soc. Clin. Oncol. 8:285, 1989 (Abstract #1111).

A41. Berd, D., Mastrangelo, M.J., Green, C., Clark, C. and Hart, E. Tumor inflammatory response induced by immunization with autologous melanoma cells conjugated to dinitrophenol (DNP). Proc. Am. Assoc. Cancer Res. 30:382, 1989 (Abstract #1515).

A42. McClay, E.F., Mastrangelo, M.J., Bellet, R. and Berd D. An effective chemo/hormonal therapy regimen for the treatment of disseminated malignant melanoma. Update I. Proc. Am. Soc. Clin. Oncol. 8:282, 1989 (Abstract #1098).

A43. Mastrangelo, M.J., Berd, D. and Maguire, H.C., Jr. Active immunotherapy of human melanoma with autologous vaccine and low dose cyclophosphamide (Cy). Proc. Second Int. Conf. Melanoma. Venice, Italy, 16-19 October 1989, p. 284.

A44. Cardi, G., Bellet, R.E., Mastrangelo, M.J. and Berd, D. Selective growth of the CD56+CD16- subset of natural killer (NK) cells in melanoma tumor - infiltrating lymphocyte (TIL) cultures. Proc. Am. Assoc. Cancer Res. 31:271, 1990 (abstract #1605).

A45. Slovin, S., Johnson, P., Patel, J., Cramer, J., Ferrone, S. and Mastrangelo, M.J. HLA-A2 in sarcomas: Isolation of immunoreactive HLA-A2 variant T cell subpopulations. Proc. Am. Assoc. Cancer Res. 31:267, 1990 (abstract #1580).

A46. Berd, D., Maguire, H.C., Jr., Mastrangelo, M.J. and Murphy, G. Lymphocytic infiltration of melanoma metastases induced by immunization with dinitrophenol (DNP) - conjugated tumor cells. Proc. Am. Assoc. Cancer Res. 31:279, 1990 (abstract #1654).

A47. Berd, D., Maguire, H.C., Jr., Clark, C., Green, C., Hart, E. and Mastrangelo, M.J. Treatment of metastatic melanoma with an autologous tumor cell vaccine: Clinical and immunological results in 64 patients. Proc. Am. Soc. Clin. Oncol. 9:278, 1990 (abstract #1079).

A48. Berd, D., Clark, C., Green, C., Hart, E. and Mastrangelo, M.J. Activation markers on tumor-infiltrating T cells induced by dinitrophenyl (DNP)-conjugated autologous melanoma vaccine. Proc. Am. Assoc. Cancer Res. 32:256, 1991 (Abstract #1523)

A49. Berd, D., McLaughlin, C.J., Hart, E., Wiebe, V.J., Mastrangelo, M.J., Bellet, R.E., and DeGregorio, M.W. Short course high-dose tamoxifen (TAM) with cytotoxic chemotherapy for metastatic melanoma. Proc. Am. Soc. Clin. Oncol. 10:291, 1991 (Abstract #1016)

A50. Kane, M., Laucius, J.F., Bellet, R., Berd, D., Mastrangelo, M., Rose, L. and Rabinowitz, M. Phase I/II trial of etoposide (E) and cefoperazone (C) in the treatment of refractory neoplasms. Proc. Am. Soc. Clin. Oncol. 10:111 1991 (Abstract #315).

A51. Somasundaram, R., Benden, A., Zaloudik, J., Sperlagh, M., Hart, E., Marks, G., Mastrangelo, M. and Herlyn, D.: Antigen-specific humoral and cellular immune response in colorectal carcinoma patients immunized with anti-idiotypic antibody GA733. Proc Am Assoc Cancer Res 33:331, 1992 (Abstract #1977).

A52. Maguire, H.C., Jr., McCue, P., Berd, D., Lattime, E.C. and Mastrangelo, M.J.: Assessment of the effects of R-24 antibody on selected parameters of immunity. Annual Meeting Society for Biological Therapy, Williamsburg, VA 10/29-11/1/92. J. Immunother. 13:65, 1993.

A53. Mastrangelo, M.J.: Review of chemotherapy and immunotherapy for melanoma. Cancer Investigation 11 (Suppl. 1): 52-54, 1993 (Abstract #43).

A54. Mastrangelo, M.J., Nathan, F., Maguire, H.C., Jr., and Berd, D.: Trials with combination chemotherapy and with active specific immunotherapy. Melanoma Res. 3 (Suppl. 1):33, 1993 (Abstract #114).

A55. Lee, S.S., Eisenlohr, L.C., McCue, P.A., Mastrangelo, M.J. and Lattime, E.C. Intravesical gene therapy: Vaccinia virus recombinants transfect murine bladder tumors and urothelium. Proc Am Assoc Cancer Res 34:337, 1993 (Abstract #1005).

A56. Berd, D., Maguire, H.C., Jr., Hart, E. and Mastrangelo, M.J.: Post-surgical adjuvant therapy of melanoma with a dinitrophenyl (DNP) - conjugated vaccine: Prolongation of disease-free and total survival. Proc Am Soc Clin Oncol 12:287, 1993 (Abstract #1319).

A57. Mastrangelo, M.J., Hart, E. and Berd, D.: Dinitrophenyl (DNP)-conjugated autologous melanoma vaccine and PEG-IL2. Ann Hematol 67 (Suppl II): A170, 1993 (Abstract #105).

A58. Lattime, E.C., Mastrangelo, M.J. and Berd, D.: Human metastatic melanoma lesions and cell lines express mRNA for IL-10. Proc Am Assoc Cancer Res (submitted).

A59. Lattime, E.C., Maguire, H.C., Jr., McCue, P.A., Eisenlohr, L.C., Berd, D., Lee, S.S. and Mastrangelo, M.J.: Infection of human melanoma cells by intratumoral vaccinia. J. Investigative Dermatol (Abstract) (Submitted 12/93).

A60. Lattime, E.C., Maguire, H.C., Jr., McCue, P.A., Eisenlohr, L.C., Berd, D., Lee, S.S. and Mastrangelo, M.J.: Gene therapy using vaccinia vectors: Repeated intratumoral infections in the presence of anti-vaccinia immunity. Proc. Am. Soc. Clin. Oncol. (submitted 12/93).

A61. Lee, S.S., Eisenlohr, L.C., McCue, P.A., Mastrangelo, M.J. and Lattime, E.C. Vaccinia virus vector mediated cytokine gene transfer for in vivo tumor immunotherapy Proc Am Assoc Cancer Res (Submitted 11/93).

A62. Nathan, F.E., Sato, T., Hart, E., Berd, D. and Mastrangelo, M.J.: Response to combination chemotherapy of liver metastases from choroidal melanoma compared with cutaneous melanoma. Proc Am Soc Clin Oncol (Submitted 12/93).

A63. Berd, D., Hart, E., Nathan, F., Fishbein, G. and Mastrangelo, M.J.: Chemotherapy of melanoma with BCNU-Dacarbazine-cisplatin + tamoxifen: A nine year perspective. Proc Am Soc Clin Oncol (Submitted 12/93).

A64. Berd, D., Maguire, H.C., Hart, E., and Mastrangelo, M.J.: Immunotherapy of melanoma with a dinitrophenyl (DNP)-conjugated vaccine: Follow-up of a post-surgical adjuvant study. Proc Am Soc Clin Oncol. (Submitted 12/93).